Summary

Respiratory Syncytial Virus Therapeutics Market – Scope of Report
TMR’s report on the global respiratory syncytial virus therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global respiratory syncytial virus therapeutics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global respiratory syncytial virus therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the respiratory syncytial virus therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global respiratory syncytial virus therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global respiratory syncytial virus therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global respiratory syncytial virus therapeutics market.

The report delves into the competitive landscape of the global respiratory syncytial virus therapeutics market. Key players operating in the global respiratory syncytial virus therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global respiratory syncytial virus therapeutics market profiled in this report.

Key Questions Answered in Global respiratory syncytial virus therapeutics Market Report
• What is the sales/revenue generated by respiratory syncytial virus therapeutics across all regions during the forecast period?
• What are the opportunities in the global respiratory syncytial virus therapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Respiratory Syncytial Virus Therapeutics Market – Research Objectives and Research Approach
The comprehensive report on the global respiratory syncytial virus therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global respiratory syncytial virus therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global respiratory syncytial virus therapeutics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Respiratory Syncytial Virus (RSV) Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. Palivizumab
6.3.2. Ribavirin
6.3.3. Others
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Dosage Form
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Dosage Form, 2017–2031
7.3.1. Oral
7.3.2. Injectable
7.3.3. Others
7.4. Market Attractiveness Analysis, by Dosage Form
8. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Drug Stores and Retail Pharmacies
8.3.2. Hospital Pharmacies
8.3.3. Others
8.4. Market Attractiveness Analysis, by Dosage Form
9. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Type, 2017–2031
10.3.1. Palivizumab
10.3.2. Ribavirin
10.3.3. Others
10.4. Market Value Forecast, by Dosage Form, 2017–2031
10.4.1. Oral
10.4.2. Injectable
10.4.3. Others
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Drug Stores and Retail Pharmacies
10.5.2. Hospital Pharmacies
10.5.3. Others
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Type
10.7.2. By Dosage Form
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Type, 2017–2031
11.3.1. Palivizumab
11.3.2. Ribavirin
11.3.3. Others
11.4. Market Value Forecast, by Dosage Form, 2017–2031
11.4.1. Oral
11.4.2. Injectable
11.4.3. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Drug Stores and Retail Pharmacies
11.5.2. Hospital Pharmacies
11.5.3. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Dosage Form
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Type, 2017–2031
12.3.1. Palivizumab
12.3.2. Ribavirin
12.3.3. Others
12.4. Market Value Forecast, by Dosage Form, 2017–2031
12.4.1. Oral
12.4.2. Injectable
12.4.3. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Drug Stores and Retail Pharmacies
12.5.2. Hospital Pharmacies
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Dosage Form
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Type, 2017–2031
13.3.1. Palivizumab
13.3.2. Ribavirin
13.3.3. Others
13.4. Market Value Forecast, by Dosage Form, 2017–2031
13.4.1. Oral
13.4.2. Injectable
13.4.3. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Drug Stores and Retail Pharmacies
13.5.2. Hospital Pharmacies
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Dosage Form
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Type, 2017–2031
14.3.1. Palivizumab
14.3.2. Ribavirin
14.3.3. Others
14.4. Market Value Forecast, by Dosage Form, 2017–2031
14.4.1. Oral
14.4.2. Injectable
14.4.3. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Drug Stores and Retail Pharmacies
14.5.2. Hospital Pharmacies
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Dosage Form
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. F. Hoffmann-La Roche Ltd.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. AstraZeneca plc
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Merck & Co., Inc.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. AbbVie, Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Valeant Pharmaceuticals International, Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. GlaxoSmithKline plc
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. ReViral Ltd.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Gilead Sciences, Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Medivir AB
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Teva Pharmaceuticals Industries Ltd.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview